Title
Local immune cell infiltration in cutaneous acute graft versus host disease.

Permalink
https://escholarship.org/uc/item/5b3978f2

Journal
International journal of women’s dermatology, 6(4)

ISSN
2352-6475

Authors
Sennett, Rachel
Jama, Burhan M
Hinds, Brian
et al.

Publication Date
2020-09-01

DOI
10.1016/j.ijwd.2020.05.009

Peer reviewed
Original Research

Local immune cell infiltration in cutaneous acute graft versus host disease

Rachel Sennett MD, PhD a, Burhan M. Jama BS b, Brian Hinds MD a, Dimitrios Tzachanis MD, PhD c, Gerald P. Morris MD, PhD b, Amanda F. Marsch MD a,⇑

⇑Corresponding author.
E-mail address: amarsch@health.ucsd.edu (A.F. Marsch).

a Department of Dermatology, University of California San Diego School of Medicine, La Jolla, CA, United States
b Department of Pathology, University of California San Diego School of Medicine, La Jolla, CA, United States
c Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA, United States

Introduction

Hematopoietic stem cell transplantation (HSCT) is used as a curative therapy for hematologic malignancies, but its therapeutic potential is limited by a number of complications, including infection, graft failure, and graft-versus-host disease (GVHD). GVHD reportedly occurs in at least 40% to 60% of transplanted patients and accounts for 15% of the mortality seen after HSCT (Strong Rodrigues et al., 2018). The severity of acute GVHD is directly related to the degree of mismatch in human leukocyte antigen (HLA), the genes encoding major histocompatibility complex proteins in humans. Additional important factors include minor histocompatibility antigens, age, myeloablative conditioning regimen, sex disparity, cytomegalovirus serology status, donor multiparity, and the use of peripheral blood stem cells (Strong Rodrigues et al., 2018). Outcomes are improved when donors and recipients are matched at high resolution with at least four HLA loci. However, although HLA matching reduces the risk of GVHD, 40% of patients receiving HLA-identical grafts still develop acute GVHD due to differences in minor histocompatibility antigens that lie outside the HLA loci (Goulmy et al., 1996).

Because the skin is often the first and most commonly affected organ in GVHD, dermatologists play a crucial role in the diagnosis and management of these patients. The cutaneous eruption of acute GVHD can present on a spectrum of severity, ranging from...
macular erythema to severe forms mimicking Stevens–Johnson syndrome or toxic epidermal necrolysis (Kavand et al., 2017). The rash usually starts within 1–3 weeks after engraftment and often appears as a maculopapular eruption that can be painful, itchy, or asymptomatic (Kavand et al., 2017). The rash typically starts on the neck, face, and acral extremities and can progress to affect the entire body. Gut or liver involvement is also typical of GVHD and may be heralded by elevated bilirubin levels, diarrhea, persistent nausea, and/or abdominal pain. The disease is classified into different stages depending on the severity of end organ involvement.

Current work attempting to understand GVHD on a more cellular level outlines three overarching stages. Initially, tissue injury incurred during the conditioning regimen promotes an exaggerated inflammatory response (Nassereddine et al., 2017). This is followed by donor T cell activation by recognition of alloantigens. Next, activated T cells release cytokines to propagate their own expansion and promote ongoing activity, in addition to aberrantly activating other immune cells. This self-perpetuating cycle ultimately leads to tissue destruction and end organ damage disproportionately affecting the skin, liver, and gut.

Skin biopsy and histopathologic analysis can contribute to the diagnosis of GVHD, but newer studies have focused on identifying biomarker panels to predict the development and severity of acute GVHD with greater accuracy (Budde et al., 2017; Paczesny et al., 2009a,b). Part of elucidating these biomarkers involves understanding what types of immune cells and cytokines are present in the skin and blood of these patients and how they might be interacting. Prior studies have looked at mRNA expression of certain genes in skin biopsies of acute GVHD and found upregulation of interleukin (IL) 2, IL-4, and interferon-gamma (Roy et al., 1995). Other investigators have found interferon-gamma and IL-17 to be abundant in murine acute GVHD of the skin, but no predominate cytokine was expressed in human skin samples (Lai et al., 2012). One study looked at the cellular profile in lesions of acute GVHD and found T cells to predominate, whereas CD191+ B cells, natural killer cells, and granulocytes were almost absent (Roy et al., 1995).

In summary, although attempts to understand the precise underpinnings of this process have identified several upregulated cytokines and related signaling cascades, a thorough understanding of the extent of immune cell dysregulation in acute GVHD is still lacking. Furthermore, there is a specific paucity of data regarding the site-specific changes that occur within affected tissues, such as the skin. The current study aimed to characterize the local immune milieu promoting cutaneous disease by comparing the presence of lymphocytes and macrophages in matched lesional and unaffected skin samples from patients with acute GVHD. A better understanding of the molecular and cellular pathways driving the initiation and progression of cutaneous GVHD would help identify early cases and potentially even prevent some of the significant morbidity associated with this diagnosis.

Methods

Patient recruitment and sample collection

Patients presenting to the dermatology clinic or those evaluated by the inpatient dermatology service between December 2018 and June 2019 were recruited to participate in the study. The inclusion criteria included HSCT patients aged ≥ 18 years at the time of consent with a rash covering at least 5% body surface area (BSA) and suspected of having acute cutaneous GVHD. The main exclusion criteria were a lack of unequivocal histopathologic findings supporting a diagnosis of acute GVHD or clinical progression of symptoms that favored an alternate diagnosis.

After obtaining informed consent, three 4-mm punch biopsies were collected from each patient, two from lesional and one from unaffected skin. In one case, a shave biopsy was taken from lesional skin. One of the lesional skin specimens was placed in formalin for routine hematoxylin and eosin processing and diagnostic reading by a dermatopathologist (B.H.) to confirm the clinical suspicion of acute GVHD. The two research samples (one lesional and one control/unaffected) were stored on saline-soaked gauze until further processing, as detailed later. Representative sites were chosen by the clinical appearance of rash (e.g., presence of erythema, edema, papules on lesional skin) or lack thereof in the case of the control specimens.

Tissue digestion and cell counting

Skin biopsy samples were processed within 4 hours of sample collection in an overnight digestion in dissociation media (RPMI 1640 with 10% FCS, 1 mg/mL collagenase, 2 mM L-glutamic acid, penicillin 100 U/mL, and streptomycin 100 μg/mL) at 37 °C to create a single cell suspension. The next morning, DNase was added to a final concentration of 200 U/mL, and the sample was incubated at room temperature for 15 min. Samples were mechanically disrupted and then iteratively washed through a series of filters (100 μm, 70 μm) using ice cold HBSS with EDTA. After each wash, samples were centrifuged for 5 min at 1200 RPM. After the final round of washing, cells were counted using trypan blue and a manual hemocytometer. Finally, cells were resuspended in 70% DMSO with FCS for storage at −80 °C while awaiting further analysis.

Fluorescence-activated cell sorting and analysis

Once five patient samples from lesional and unaffected skin were collected, the samples were thawed, washed, and resuspended prior to fluorescence-activated cell sorting (FACS) analysis. Antibodies were used to identify macrophages (CD14, HCD14), lymphocytes (CD3, HIT3a), and lymphocyte subtypes (CD4 OKT4, CD8 HIT8a; Biolegend, San Diego, CA). The samples were analyzed using BD FACSCanto or LSR II instruments with FACSDiva software, and data were analyzed using FlowJo, version 10, along with Prism software (BD Biosciences, San Jose, CA). Statistical analysis was performed in Prism using the Wilcoxon matched pairs signed rank test.

Results

Patient characteristics and outcomes

Six patients met the inclusion criteria for the study and were enrolled. One patient went on to develop upper respiratory symptoms and an up trending adenovirus titer and was therefore excluded from the study based on clinical suspicion for a concomitant viral exanthem. The baseline characteristics of the five patients included in the study are outlined in Table 1. Patient age ranged from 45 to 71 years, with a mean age of 59 ± 0.8 years. Patients had diverse indications for HSCT. Four of five patients had matched unrelated donors, and the fifth patient had an HLA-matched sibling donor. Three transplants were sourced from peripheral blood, and the other two were sourced from bone marrow.

The onset of cutaneous GVHD occurred prior to post-transplant day 100 in all five cases, and all patients presented with some variation of pink macules and/or papules scattered over the extremities and trunk. Representative images are shown for all patients in Fig. 1, some of which highlight the specific sites from which samples were collected for additional study. The median time after
transplant to onset of rash was 35 days. Four of five patients displayed clinical stage 2 (maculopapular rash involving 25%-50% BSA) cutaneous GVHD, as defined by the Glucksberg grading system, which places an emphasis on the degree of BSA involved. The fifth patient demonstrated slightly more widespread disease, with >80% BSA involved, which indicated stage 3 GVHD of the skin.

On pathology, four of five samples were classified as Lerner grade 2 lichenoid. One patient was classified as Lerner grade 1 mostly macular, which placed an emphasis on the degree of rash on >50% of skin, bilirubin 2–3 mg/dL, diarrhea 500–1000 mL/day or severe abdominal pain with or without ileus; and IV (generalized erythroderma with bullae formation, or bilirubin >15 mg/dL).

Clinical stage of GVHD: Skin: Stage 0 (no rash, or no rash attributable to acute GVHD); Stage 1 (maculopapular rash, <25% of BSA); Stage 2 (maculopapular rash, 25–50% of BSA); and Stage 4 (generalized erythroderma, >50% of BSA); and Stage 4 (generalized erythroderma with bullae formation and/or desquamation).

### Table 1
Clinical characteristics of all five patients.

| Patient | Age (y), sex | Diagnosis | Type of preconditioning regimen | Date of transplant | Type of transplant | Stem cell source | Date onset rash | Biopsy sites |
|---------|--------------|-----------|---------------------------------|-------------------|-------------------|-----------------|----------------|--------------|
| 1       | 59, F        | DLBL; Richter's syndrome | Fludarabine and busulfan | 12/11/18 | Matched unrelated donor; allogeneic SCT | Bone marrow | Day 27 | Left back; right flank |
| 2       | 45, M        | Plasma cell leukemia | Cytotoxan/total body irradiation | 9/18/18 | Matched unrelated donor; allogeneic SCT | Peripheral blood | Day 98 | Right leg; right chest |
| 3       | 52, F        | DLBL | Thiotepa-fludarabine-cyclophosphamide; Rituxan | 2/11/19 | Sibling allogeneic SCT (after relapse of autologous) | Peripheral blood | Day 29 | Right hand; right forearm |
| 4       | 71, M        | Accelerated phase CML | Fludarabine and busulfan | 1/26/19 | Matched unrelated donor; allogeneic SCT | Bone marrow | Day 47 | Left abdomen; right leg |
| 5       | 68, M        | Accelerated phase CML | Reduced intensity conditioning with fludarabine and melphalan | 4/26/19 | Matched unrelated donor; allogeneic SCT | Peripheral blood | Day 35 | Right back; left hand |

BSA, body surface area; CML, chronic myelogenous leukemia; CMV, cytomegalovirus; DLBL, diffuse large B-cell lymphoma; GVHD, graft-versus-host disease; HLA, human leukocyte antigen; SCT, stem cell transplant.

Overall grade of acute GVHD at diagnosis: 0 (none); 1 (rash on <50% of skin, no liver or gut involvement); II (rash on >50% of skin, bilirubin 2–3 mg/dL, diarrhea 500–1000 mL/day or persistent nausea); III (Bilirubin 3–15 mg/dL, or gut stage 2–4, diarrhea >1000 mL/day or severe abdominal pain with or without ileus); and IV (generalized erythroderma with bullae formation, or bilirubin >15 mg/dL). Clinical stage of GVHD (skin); Stage 0 (no rash, or no rash attributable to acute GVHD); Stage 1 (maculopapular rash, <25% of BSA); Stage 2 (maculopapular rash, 25–50% of BSA); and Stage 4 (generalized erythroderma, >50% of BSA); and Stage 4 (generalized erythroderma with bullae formation and/or desquamation).

### Table 1 (cont'd)

| Patient | Pathology grade | Morphology | Distribution of rash | Donor characteristics | Recipient characteristics | Clinical stage of GVHD: Liver | Clinical stage of GVHD: Gut |
|---------|----------------|------------|----------------------|-----------------------|--------------------------|-----------------------------|----------------------------|
| 1       | Lerner grade 2 | Maculopapular | Trunk, face | Male Blood type: O+ CMV positive HLA 10/10 match | Female Blood type: A + CMV negative | 3 | 0 |
| 2       | Lerner grade 1 | Mostly macular | Trunk, proximal extremities | Blood type: O+ CMV negative 8/8 (with a single DQ mismatch) | Blood type: A + CMV negative | 2 | 0 |
| 3       | Lerner grade 2 | Mostly macular erythema | Neck, back with macular erythema; palms, soles with erythema and scale; firm papules on dorsal hands | Male sibling Blood type: A+ CMV negative | Female Blood type: A + CMV negative | 2 | 0 |
| 4       | Lerner grade 2 | Maculopapular | Trunk, upper extremities, dorsal hands, proximal lower extremities | Male Blood type: B +D+ CMV negative 10/10 HLA match | Male Blood type: B +D+ CMV positive | 2 | 0 |
| 5       | Lerner grade 2 | Mostly macular with follicular prominence BSA >80% | Trunk, proximal extremities, buttocks; spares distal extremities | Blood type: O+ CMV negative 10/10 HLA match | Blood type: O + CMV negative | 2 | 0 |

### Table 1 (cont'd)

| Patient | Clinical stage of GVHD: Liver | Overall GVHD grade | Treatment | Clinical course |
|---------|-------------------------------|--------------------|-----------|-----------------|
| 1       | 0                             | 1                  | Fluocinonide ointment; oral prednisone | Resolved over 3 months, then tapered off oral prednisone; progressed to have mild chronic GVHD of the liver |
| 2       | 0                             | 1                  | Fluocinonide ointment; oral prednisone | Resolved over 4 months, tapered off prednisone |
| 3       | 0                             | 1                  | Triamcinolone cream; oral prednisone | Improved over 2–3 months, was able to taper to physiologic doses of prednisone |
| 4       | 0                             | 1                  | Cloretasol ointment; oral prednisone | Deceased |
| 5       | 0                             | 1                  | Cloretasol cream (Had bad reaction to oral prednisone in past so did not use) | Resolved over 3 months |
Characterization of immune cells in acute cutaneous GVHD

The total number of cells initially harvested after tissue processing is displayed in Table 2, with counts ranging from $0.70 \times 10^6$ to $4.08 \times 10^6$ total cells from each primary sample. Viability dye confirmed that >68% of cells for all samples were still alive after storage. FACS analysis revealed the heterogeneous nature of each patient’s presentation. The percent of CD3$^+$ lymphocytes was increased in lesional skin compared with unaffected skin in three of five cases (Fig. 3A). In four of five cases, the ratio of CD4$^+$ to CD8$^+$ lymphocytes increased in lesional compared with unaffected skin (Fig. 3B). In contrast, CD14$^+$ macrophages were less abundant in lesional compared with unaffected skin in three of five cases, but overall composed only a fraction of immune cells in the analyzed tissue, with representation ranging from 0.2% to 5.9% of all live cells (Fig. 3C).

Discussion

To better characterize the dysregulated and damaging inflammatory infiltrates in acute cutaneous GVHD, this investigation collected samples from affected lesional skin and clinically unaffected skin from five patients. Primary tissue was processed for FACS analysis with well-established cell surface markers for CD14$^+$ macrophages, CD3$^+$ lymphocytes, and CD4/CD8 T cell subtypes, with the goal to explore changes in the immune cell landscape between clinically involved and spared skin.

Overall, the immune cell presence in lesional versus unaffected skin varied among all five patients, and although the median number of lymphocytes as a percentage of live cells did increase from unaffected to lesional skin, this was not a statistically significant change. There also appeared to be a modest shift in lymphocyte subtype prevalence, with an increased CD4$^+$:CD8$^+$ T cell ratio in lesional versus unaffected skin. Prior studies have highlighted an increase in donor CD4$^+$ T cells in cutaneous GVHD, at least in animal models. Of note, the host versus donor origin of these lymphocytes could not be determined with the current study design (Boieri et al., 2017). Interestingly, two patients appeared to have a greater percentage of CD3$^+$ lymphocytes in clinically unaffected skin compared with a corresponding lesional sample. The sites suspected to be uninvolved in those two patients might have had subclinical activity that evolved to a demonstrable dermatitis in the days after biopsy. On the other hand, this observation might underscore the idea that GVHD is a systemic reaction, with overactivated immune cells present throughout the blood, skin, and other tissues. Additional studies to probe the transcriptional activity and clonal expansion of specific cells at unique lesional sites could be more revealing than an analysis of surface markers alone.

Three of five patients were found to have fewer CD14$^+$ macrophages in lesional compared with unaffected skin, although prevalence as a percentage of live cells varied widely among patients. Monocytes and monocyte-derived macrophages are thought to contribute to GVHD, with evidence suggesting both proinflammatory and protective roles (Ito and Fujino, 2019; Santos e Sousa et al., 2018). In the skin, macrophage infiltration has been associ-
ated with steroid unresponsiveness and increased mortality (Nishiwaki et al., 2009; Terakura et al., 2015). A deficiency in classical circulating monocytes was also shown to predict increased mortality (de Molla et al., 2019). In this cohort study, the decreased confluence of CD14+ macrophages in lesional skin could reflect the relatively straightforward course for most patients; most recovered from acute GVHD without significant sequelae. The one individual who did prove to have steroid-refractory GVHD (patient 4) demonstrated fewer CD3+ lymphocytes in lesional skin compared with other individuals, but with a marked shift toward CD4+ predominance and a slight increase in CD14+ macrophages in the lesional skin.

The patients recruited to this pilot study had varied histories and exposures, indications for transplant, conditioning regimens, and donor sources. For any one patient, all of these factors, among others, are considered when planning a transplant because some appear to confer a greater risk of subsequent GVHD for reasons not yet well understood (Strong Rodrigues et al., 2018). All five patients initially presented with different degrees of skin involvement and distinct immune cell profiles, possibly reflecting the heterogeneous nature of their disease and transplant conditions. If different aspects of a patient’s history or transplant parameters might predispose to a specific clinical appearance at presentation with consistent molecular or cellular changes as well, these may represent unique targets for intervention.

The limitations of this study include the small sample size and the diversity of cases recruited. Future, more involved studies will be necessary to gather information about specific conditioning regimens, donor characteristics, initial diagnosis, and age to understand whether the molecular and immune cell landscape changes adjust for these factors. In addition, only a few cell surface markers were explored in this initial examination owing to limited

| Sample     | Cell counts |
|------------|-------------|
| 1 Unaffected | $1.48 \times 10^6$ |
| 1 Lesional   | $1.71 \times 10^6$ |
| 2 Unaffected | $4.08 \times 10^6$ |
| 2 Lesional   | $1.38 \times 10^6$ |
| 3 Unaffected | $0.73 \times 10^6$ |
| 3 Lesional   | $0.70 \times 10^6$ |
| 4 Unaffected | $1.30 \times 10^6$ |
| 4 Lesional   | $2.40 \times 10^6$ |
| 5 Unaffected | $1.27 \times 10^6$ |
| 5 Lesional   | $1.10 \times 10^6$ |

Fig. 2. Representative histopathology results at 10× magnification from all five patients. (A) Patient 1, (B) Patient 2, (C) Patient 3, (D) Patient 4, and (E) Patient 5.
Conclusion

In this small pilot study of five patients, an initial investigation into the immune cell types underlying acute cutaneous GVHD revealed the variable presence of macrophages and T-lymphocytes in both lesional and unaffected skin, possibly reflecting the unique response of each patient to an individualized ablation and transplant regimen. This study emphasizes the importance of developing a patient-centric approach when considering GVHD prophylaxis and treatment in the setting of planned HSCT. Future studies to examine the nature of the cutaneous immune infiltrate in even greater detail, through RNA-sequencing or T-cell receptor clonotyping, will help elucidate the molecular mechanisms underlying lymphocyte activation and targeting, potentially revealing additional biomarkers to aid in diagnosis or therapeutic targets to improve patient outcomes.

Conflict of Interest

None.

Funding

The Women’s Dermatologic Society Academic Research Award.

Study Approval

The author(s) confirm that any aspect of the work covered in this manuscript that has involved human patients has been conducted with the ethical approval of all relevant bodies.

References

Boieri M, Shah P, Jalapothu D, Zaitseva O, Walter L, Rolstad B, et al. Rat acute GvHD is Th1 driven and characterized by predominant donor CD4+ T-cell infiltration of skin and gut. Exp Hematol 2017;50(33–45) e3.

Budde H, Papert S, Maas JH, Reichardt HM, Wulf G, Hasenkamp J, et al. Prediction of graft-versus-host disease: A biomarker panel based on lymphocytes and cytokines. Ann Hematol 2017;96(7):1127–33.

de Molla VC, Gonçalves MV, Konura EY, Colturato V, Ikoma MV, Zecchin VG, et al. Classical monocyte deficiency calculated by the mono-index can predict mortality in allogeneic hematopoietic stem cell transplantation patients. Blood 2019;134(Suppl 1):5666.
Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, Vossen J, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996;334(5):281–5.

Ito M, Fujino M. Macrophage-mediated complications after stem cell transplantation. Pathol Int 2019;69(12):679–87.

Kavand S, Lehman JS, Hashemi S, Gibson LE, et-Azhary RA. Cutaneous manifestations of graft-versus-host disease: role of the dermatologist. Int J Dermatol 2017;56(2):131–40.

Lai HY, Chou TY, Tseng CH, Lee OKS. Cytokine profiles in various graft-versus-host disease target organs following hematopoietic stem cell transplantation. Cell Transplant 2012;21(9):2033–45.

Nassereddine S, Rafei H, Elbahesh E, Tabbara I. Acute graft versus host disease: a comprehensive review. Anticancer Res 2017;37(4):1547–55.

Nishiwaki S, Terakura S, Ito M, Goto T, Seto A, Watanabe K, et al. Impact of macrophage infiltration of skin lesions on survival after allogeneic stem cell transplantation: a clue to refractory graft-versus-host disease. Blood 2009;114(14):3113–6.

Paczysny S, Krijanovski OL, Braun TM, Choi SW, Clouthier SG, Kuick R, et al. A biomarker panel for acute graft-versus-host disease. Blood 2009a;113(2):273–8.

Paczysny S, Levine JE, Braun TM, Ferrara JL. Plasma biomarkers in graft-versus-host disease: a new era? Biol Blood Marrow Transplant 2009b;15(1 Suppl):33–8.

Roy J, Blazar BR, Ochs L, Weisdorf DJ. The tissue expression of cytokines in human acute cutaneous graft-versus-host disease. Transplantation 1995;60(4):343–8.

Santos e Sousa P, Bennett CL, Chakraverty R. Unraveling the mechanisms of cutaneous graft-versus-host disease. Front Immunol 2018;9:963.

Strong Rodrigues K, Oliveira-Ribeiro C, de Abreu Fiuza Gomes S, Knobler R. Cutaneous graft-versus-host disease: Diagnosis and treatment. Am J Clin Dermatol 2018;19(1):33–30.

Terakura S, Martin PJ, Shulman HM, Storer BE. Cutaneous macrophage infiltration in acute GvHD. Bone Marrow Transplant 2015;50(8):1135–7.